Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES HARPER

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1063620961
CMS profile
229937
Location
NORFOLK, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,808.80

124 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,808.80 124

By paying entity

PY2020 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES HARPER

NPI 1063620961 · CMS profile ID 229937

Allopathic & Osteopathic Physicians / Internal Medicine

NORFOLK, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063620961?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES HARPER, NPI 1063620961, CMS profile ID 229937. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063620961?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). CHARLES HARPER, NPI 1063620961, CMS profile ID 229937. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063620961?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
CHARLES HARPER, NPI 1063620961, CMS profile ID 229937, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1063620961?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

124 matching records · $1,808.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 124 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 124.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $15.6908/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744870489 CMS
Lilly USA, LLC $12.9608/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728361463 CMS
PFIZER INC. $7.6307/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743744839 CMS
Arbor Pharmaceuticals, Inc. $13.5007/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735728617 CMS
Amarin Pharma Inc. $21.1907/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739839590 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.1307/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720774317 CMS
PFIZER INC. $11.3407/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743743733 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $13.6407/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737538575 CMS
AstraZeneca Pharmaceuticals LP $12.6307/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736171147 CMS
Novo Nordisk Inc $10.5307/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745024923 CMS
Avanir Pharmaceuticals, Inc. $14.3507/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722211523 CMS
Mannkind Corporation $13.2807/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752671573 CMS
Novo Nordisk Inc $12.0607/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744789105 CMS
Lilly USA, LLC $12.2207/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728361461 CMS
AstraZeneca Pharmaceuticals LP $14.6107/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735998209 CMS
Novo Nordisk Inc $15.2406/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744762261 CMS
Janssen Pharmaceuticals, Inc $11.2106/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719077141 CMS
Astellas Pharma US Inc $12.5406/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718331157 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.2006/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720774323 CMS
IRONWOOD PHARMACEUTICALS, INC $13.8206/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749828745 CMS
Novo Nordisk Inc $4.8506/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744775283 CMS
Lilly USA, LLC $12.7506/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728364907 CMS
Lilly USA, LLC $2.5306/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728368367 CMS
Merck Sharp & Dohme Corporation $18.1906/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747677635 CMS
Mannkind Corporation $17.0806/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 752671571 CMS
AstraZeneca Pharmaceuticals LP $12.2906/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736239193 CMS
SANOFI-AVENTIS U.S. LLC $13.2306/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744258787 CMS
Novo Nordisk Inc $11.4306/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744696599 CMS
Novo Nordisk Inc $13.2706/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744698423 CMS
Avanir Pharmaceuticals, Inc. $14.4506/01/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722211457 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.7605/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720774329 CMS
Janssen Pharmaceuticals, Inc $14.1205/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719077139 CMS
AstraZeneca Pharmaceuticals LP $15.8605/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736315505 CMS
Astellas Pharma US Inc $14.3305/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718331155 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.1705/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720774333 CMS
IRONWOOD PHARMACEUTICALS, INC $17.4605/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749820801 CMS
GlaxoSmithKline, LLC. $11.4505/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738569311 CMS
PFIZER INC. $9.4505/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743725711 CMS
Janssen Pharmaceuticals, Inc $14.3905/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719077135 CMS
IRONWOOD PHARMACEUTICALS, INC $21.8304/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749818883 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.7604/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720774337 CMS
AstraZeneca Pharmaceuticals LP $21.2804/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735854127 CMS
Janssen Pharmaceuticals, Inc $9.1104/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719077137 CMS
Novo Nordisk Inc $10.9604/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744666973 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.7604/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720774341 CMS
AstraZeneca Pharmaceuticals LP $11.1804/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735895633 CMS
AstraZeneca Pharmaceuticals LP $19.6304/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 736295691 CMS
AstraZeneca Pharmaceuticals LP $13.3203/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735982031 CMS
Amarin Pharma Inc. $11.7303/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739827273 CMS
Novo Nordisk Inc $9.5803/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744639661 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,497.82 109
PY2020 $1,808.80 124
PY2021 $2,387.87 153
PY2022 $1,680.65 120
PY2023 $3,225.31 104
PY2024 $1,261.75 69
PY2025 $1,279.77 77

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,597,319.56 478
PY2024 Principal investigator $5,628,700.46 398
PY2023 Principal investigator $5,967,726.31 1,617
PY2022 Principal investigator $10,695,952.45 1,759
PY2021 Principal investigator $2,712,728.19 172
PY2020 Principal investigator $1,871,094.84 66
PY2019 Principal investigator $595,554.83 81

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

478 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $18,800.00 12/31/2025 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228805184
Principal investigator 1 PFIZER INC. $2,251.88 12/31/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228816924
Principal investigator 1 SANOFI PASTEUR INC. $2,160.00 12/26/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226089964
Principal investigator 1 ModernaTX, Inc. $1,940.86 12/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950004
Principal investigator 1 SANOFI PASTEUR INC. $3,500.00 12/22/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226115291
Principal investigator 1 SANOFI PASTEUR INC. $1,811.00 12/22/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226115299
Principal investigator 1 ModernaTX, Inc. $3,324.24 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252949998
Principal investigator 1 ModernaTX, Inc. $199.80 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950028
Principal investigator 1 ModernaTX, Inc. $29.50 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950046
Principal investigator 1 ModernaTX, Inc. $68.85 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950052
Principal investigator 1 ModernaTX, Inc. $148.50 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950084
Principal investigator 1 ModernaTX, Inc. $6,959.70 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994410
Principal investigator 1 ModernaTX, Inc. $16,876.75 12/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994414
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271802
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271804
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271806
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271808
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271810
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271812
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271814
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271816
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271818
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271820
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271822
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271824
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271826
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271828
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271830
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271832
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185271834
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273020
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273028
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273030
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273032
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273034
Principal investigator 1 Seqirus USA Inc $3,518.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185273044
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279629
Principal investigator 1 Seqirus USA Inc $47.60 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185279631
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280237
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280239
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280241
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280243
Principal investigator 1 Seqirus USA Inc $406.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280245
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280729
Principal investigator 1 Seqirus USA Inc $819.00 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185280731
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282663
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282665
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282667
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282669
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282671
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282673
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282675
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282677
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282679
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282681
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282683
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282685
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282687
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282689
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282691
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282693
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282695
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282697
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282699
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282701
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282703
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282705
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282707
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282709
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282711
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282713
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282715
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282717
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282719
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282721
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282723
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282993
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282995
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282997
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185282999
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283001
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283003
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283005
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283007
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283009
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283011
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283013
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283015
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283017
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283019
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283021
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283023
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283025
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283027
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283029
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283031
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283033
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283035
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283037
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283039
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283041
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283043
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283045
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283047
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283049
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283051
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283053
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283055
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283057
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283059
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283061
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283063
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283065
Principal investigator 1 Seqirus USA Inc $1,061.20 12/19/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185283067
Principal investigator 1 Janssen Research & Development, LLC $122.00 12/18/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175240871
Principal investigator 1 Seqirus USA Inc $406.00 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274106
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274240
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274242
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274244
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274246
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274248
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274250
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274252
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274254
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274256
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274258
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274260
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274262
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274264
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274266
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274268
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274270
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274272
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274274
Principal investigator 1 Seqirus USA Inc $1,019.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274294
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274492
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274496
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274498
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274500
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274502
Principal investigator 1 Seqirus USA Inc $1,061.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274504
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274810
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274812
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274814
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274816
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274818
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274820
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274822
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274824
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274826
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274828
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274830
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274832
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274834
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274836
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274838
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274840
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274842
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274844
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274846
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274848
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274850
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274852
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274854
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274856
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274858
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274860
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274862
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274864
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274866
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274868
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274870
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274872
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274874
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274876
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274878
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274880
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274882
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274884
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274886
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274888
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274890
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274892
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274894
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274896
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274898
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274900
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274902
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274904
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274906
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274908
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274910
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274912
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274914
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274916
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274918
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274920
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274922
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185274924
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275098
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275100
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275102
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275104
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275106
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275108
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275110
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275112
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275114
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275116
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275118
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275120
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275122
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275124
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275126
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275128
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275131
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275134
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275136
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275138
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275140
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275142
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275144
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275146
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275148
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275150
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275152
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275154
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275156
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275158
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275160
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275162
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275164
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275166
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275168
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275170
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275172
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275174
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275176
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275178
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275180
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275182
Principal investigator 1 Seqirus USA Inc $3,518.20 12/18/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185275184
Principal investigator 1 ModernaTX, Inc. $10,000.00 12/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) No dispute reported 06/30/2026 1252946504
Principal investigator 1 PFIZER INC. $585.00 12/16/2025 Non-covered Recipient Entity
Velocity Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228805190
Principal investigator 1 ModernaTX, Inc. $800.00 12/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994342
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228809406
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228809413
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228809418
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228809454
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228809460
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228809465
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228809494
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228809500
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228809512
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228809516
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228809521
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228809580
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228809666
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228810090
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228810098
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228810102
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228810142
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228810439
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228810444
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Velocity Clinical Research Norfolk
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228810450
Principal investigator 1 ModernaTX, Inc. $500.00 12/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252950068
Principal investigator 1 ModernaTX, Inc. $4,676.00 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950002
Principal investigator 1 ModernaTX, Inc. $3,426.84 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950006
Principal investigator 1 ModernaTX, Inc. $29.50 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950030
Principal investigator 1 ModernaTX, Inc. $324.50 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950048
Principal investigator 1 ModernaTX, Inc. $278.35 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994320
Principal investigator 1 ModernaTX, Inc. $36,731.75 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994380
Principal investigator 1 ModernaTX, Inc. $7,503.10 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994416
Principal investigator 1 ModernaTX, Inc. $1,444.00 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010368
Principal investigator 1 ModernaTX, Inc. $425.00 11/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010378
Principal investigator 1 ModernaTX, Inc. $105.00 11/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994300
Principal investigator 1 ModernaTX, Inc. $30,000.00 11/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) No dispute reported 06/30/2026 1252946502
Principal investigator 1 ModernaTX, Inc. $1,600.00 11/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252949996
Principal investigator 1 ModernaTX, Inc. $800.00 11/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950032
Principal investigator 1 SANOFI PASTEUR INC. $294,184.80 11/14/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226115310
Principal investigator 1 Seqirus USA Inc $3,419.20 11/12/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809772
Principal investigator 1 Seqirus USA Inc $939.60 11/12/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809777
Principal investigator 1 SANOFI PASTEUR INC. $2,062.90 11/05/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226090349
Principal investigator 1 Seqirus USA Inc $939.60 10/31/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809951
Principal investigator 1 Seqirus USA Inc $3,419.20 10/31/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809954
Principal investigator 1 ModernaTX, Inc. $23,088.80 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252949990
Principal investigator 1 ModernaTX, Inc. $28,272.00 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252950038
Principal investigator 1 ModernaTX, Inc. $1,846.80 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950050
Principal investigator 1 ModernaTX, Inc. $29.50 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950076
Principal investigator 1 ModernaTX, Inc. $24,818.75 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994294
Principal investigator 1 ModernaTX, Inc. $17,794.65 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994302
Principal investigator 1 ModernaTX, Inc. $717.92 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994304
Principal investigator 1 ModernaTX, Inc. $7,997.68 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994314
Principal investigator 1 ModernaTX, Inc. $6,925.50 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994344
Principal investigator 1 ModernaTX, Inc. $29,176.94 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994348
Principal investigator 1 ModernaTX, Inc. $1,670.10 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994364
Principal investigator 1 ModernaTX, Inc. $26,291.25 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994392
Principal investigator 1 ModernaTX, Inc. $7,503.10 10/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994420
Principal investigator 1 PFIZER INC. $3,675.00 10/25/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228825189
Principal investigator 1 SANOFI PASTEUR INC. $43,967.70 10/23/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226090318
Principal investigator 1 Seqirus USA Inc $360.34 10/13/2025 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297728
Principal investigator 1 SANOFI PASTEUR INC. $24,754.80 10/10/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226115080
Principal investigator 1 ModernaTX, Inc. $16,963.20 09/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252949976
Principal investigator 1 ModernaTX, Inc. $29.50 09/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950034
Principal investigator 1 ModernaTX, Inc. $13,406.40 09/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252950040
Principal investigator 1 ModernaTX, Inc. $4,453.60 09/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994290
Principal investigator 1 ModernaTX, Inc. $7,419.50 09/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994386
Principal investigator 1 Janssen Research & Development, LLC $6,000.00 09/24/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175239087
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 09/24/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175239497
Principal investigator 1 Janssen Research & Development, LLC $1,260.00 09/24/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175239756
Principal investigator 1 Janssen Research & Development, LLC $3,255.00 09/24/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175240116
Principal investigator 1 Janssen Research & Development, LLC $2,250.00 09/24/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175240208
Principal investigator 1 ModernaTX, Inc. $902.11 09/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252949992
Principal investigator 1 ModernaTX, Inc. $11,477.79 09/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252949994
Principal investigator 1 ModernaTX, Inc. $6,758.18 09/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252950044
Principal investigator 1 ModernaTX, Inc. $448.97 09/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252950066
Principal investigator 1 ModernaTX, Inc. $33.75 09/23/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH-NORFOLK
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950026
Principal investigator 1 Janssen Research & Development, LLC $268.80 09/22/2025 Non-covered Recipient Entity
Meridian Clinic Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175244116
Principal investigator 1 Janssen Research & Development, LLC $570.00 09/19/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175239781
Principal investigator 1 Seqirus USA Inc $946.80 09/18/2025 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297752
Principal investigator 1 Seqirus USA Inc $110.98 09/18/2025 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297756
Principal investigator 1 Seqirus USA Inc $111.30 09/18/2025 Non-covered Recipient Entity
Meridian Clinical Research
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185297760
Principal investigator 1 ModernaTX, Inc. $1,350.00 09/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950086
Principal investigator 1 ModernaTX, Inc. $400.00 09/15/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994266
Principal investigator 1 ModernaTX, Inc. $800.00 09/08/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994390
Principal investigator 1 Janssen Research & Development, LLC $3,600.00 09/01/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175239579
Principal investigator 1 ModernaTX, Inc. $4,676.00 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950000
Principal investigator 1 ModernaTX, Inc. $383.50 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950008
Principal investigator 1 ModernaTX, Inc. $372.40 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252950024
Principal investigator 1 ModernaTX, Inc. $4,851.90 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950074
Principal investigator 1 ModernaTX, Inc. $6,648.48 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950078
Principal investigator 1 ModernaTX, Inc. $341.55 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950082
Principal investigator 1 ModernaTX, Inc. $5,819.98 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950088
Principal investigator 1 ModernaTX, Inc. $6,853.68 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950090
Principal investigator 1 ModernaTX, Inc. $35.00 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994270
Principal investigator 1 ModernaTX, Inc. $992.75 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994292
Principal investigator 1 ModernaTX, Inc. $7,879.30 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994336
Principal investigator 1 ModernaTX, Inc. $6,123.70 08/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994362
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $2,119.00 08/20/2025 Non-covered Recipient Entity
Meridian Clinical Research
BAY 948862, A parallel-group treatment, Phase 2, double-blind, three-arm study to assess efficacy and safety of finerenone plus empagliflozin compared with either finerenone or empagliflozin in partic No dispute reported 06/30/2026 1225408584
Principal investigator 1 ModernaTX, Inc. $75.00 08/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994262
Principal investigator 1 ModernaTX, Inc. $1,000.00 08/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994310
Principal investigator 1 ModernaTX, Inc. $70.00 08/20/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994350
Principal investigator 1 ModernaTX, Inc. $105.00 08/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994308
Principal investigator 1 ModernaTX, Inc. $1,797.40 08/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994318
Principal investigator 1 ModernaTX, Inc. $8,628.85 08/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994324
Principal investigator 1 ModernaTX, Inc. $400.00 08/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994398
Principal investigator 1 PFIZER INC. $5,800.00 08/16/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1228843292
Principal investigator 1 ModernaTX, Inc. $750.00 08/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950054
Principal investigator 1 Seqirus USA Inc $14,500.00 08/01/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276902
Principal investigator 1 Seqirus USA Inc $27,126.40 08/01/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276920
Principal investigator 1 Janssen Research & Development, LLC $6,844.00 07/31/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175239586
Principal investigator 1 Janssen Research & Development, LLC $476.00 07/31/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175240469
Principal investigator 1 Seqirus USA Inc $2,000.00 07/30/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185276970
Principal investigator 1 ModernaTX, Inc. $461.52 07/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994274
Principal investigator 1 ModernaTX, Inc. $21,993.62 07/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994276
Principal investigator 1 ModernaTX, Inc. $26,932.56 07/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994316
Principal investigator 1 ModernaTX, Inc. $7,361.55 07/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994346
Principal investigator 1 ModernaTX, Inc. $12,720.00 07/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010366
Principal investigator 1 Janssen Research & Development, LLC $2,700.00 07/01/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175239276
Principal investigator 1 ModernaTX, Inc. $1,500.00 06/30/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994268
Principal investigator 1 ModernaTX, Inc. $5,475.80 06/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994296
Principal investigator 1 ModernaTX, Inc. $8,934.75 06/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994298
Principal investigator 1 ModernaTX, Inc. $3,618.55 06/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994322
Principal investigator 1 Janssen Research & Development, LLC $16,394.00 06/26/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175240213
Principal investigator 1 PFIZER INC. $2,670.00 06/26/2025 Non-covered Recipient Entity
Meridian Clinical Research LLC
A PHASE 12 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST VARICELLA ZOSTER VIRUS IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228852351
Principal investigator 1 ModernaTX, Inc. $6,798.20 06/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252950070
Principal investigator 1 ModernaTX, Inc. $500.00 06/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994280
Principal investigator 1 ModernaTX, Inc. $245.00 06/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994340
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/25/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994404
Principal investigator 1 Seqirus USA Inc $89,869.05 06/25/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects >18 Years of Age No dispute reported 06/30/2026 1185277089
Principal investigator 1 ModernaTX, Inc. $7,670.30 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994286
Principal investigator 1 ModernaTX, Inc. $16,876.75 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994412
Principal investigator 1 ModernaTX, Inc. $3,061.85 06/18/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994426
Principal investigator 1 ModernaTX, Inc. $48,640.00 06/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010376
Principal investigator 1 SANOFI PASTEUR INC. $198,416.40 06/12/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226115285
Principal investigator 1 SANOFI PASTEUR INC. $109,571.00 06/12/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226115295
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,000.00 06/11/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185541340
Principal investigator 1 Seqirus USA Inc $187.50 06/11/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects >18 Years of Age No dispute reported 06/30/2026 1185277087
Principal investigator 1 Seqirus USA Inc $1,895.00 06/11/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects >18 Years of Age No dispute reported 06/30/2026 1185277091
Principal investigator 1 Seqirus USA Inc $580.00 06/11/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects >18 Years of Age No dispute reported 06/30/2026 1185277093
Principal investigator 1 Seqirus USA Inc $1,500.00 06/11/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects >18 Years of Age No dispute reported 06/30/2026 1185277095
Principal investigator 1 SANOFI PASTEUR INC. $500.00 06/09/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226115205
Principal investigator 1 ModernaTX, Inc. $825.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010364
Principal investigator 1 ModernaTX, Inc. $25,375.00 06/05/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010370
Principal investigator 1 SANOFI PASTEUR INC. $14,263.90 06/02/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226115110
Principal investigator 1 ModernaTX, Inc. $11,600.00 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252949978
Principal investigator 1 ModernaTX, Inc. $129,618.00 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252949980
Principal investigator 1 ModernaTX, Inc. $5,000.00 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252949982
Principal investigator 1 ModernaTX, Inc. $47,120.00 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252949986
Principal investigator 1 ModernaTX, Inc. $9,000.00 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252949988
Principal investigator 1 ModernaTX, Inc. $2,802.00 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252950042
Principal investigator 1 ModernaTX, Inc. $6,958.75 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994288
Principal investigator 1 ModernaTX, Inc. $25,811.50 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994358
Principal investigator 1 ModernaTX, Inc. $7,210.50 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994370
Principal investigator 1 ModernaTX, Inc. $686.85 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994384
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate the Safety and Immunogenicity of a Second Generation Structurally Designed Pandemic Influenza H5 HA mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226090379
Principal investigator 1 ModernaTX, Inc. $1,002.00 05/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010358
Principal investigator 1 ModernaTX, Inc. $188,480.00 05/22/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010360
Principal investigator 1 AstraZeneca Pharmaceuticals LP $18,050.00 05/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185541342
Principal investigator 1 ModernaTX, Inc. $650.00 05/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252950018
Principal investigator 1 ModernaTX, Inc. $8,750.00 05/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252950092
Principal investigator 1 ModernaTX, Inc. $202.50 05/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994278
Principal investigator 1 ModernaTX, Inc. $750.00 05/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994406
Principal investigator 1 Janssen Research & Development, LLC $368.00 05/20/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175241115
Principal investigator 1 ModernaTX, Inc. $550.00 05/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252950014
Principal investigator 1 ModernaTX, Inc. $573.16 05/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252950016
Principal investigator 1 ModernaTX, Inc. $1,200.00 05/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252950020
Principal investigator 1 ModernaTX, Inc. $29,155.32 05/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults No dispute reported 06/30/2026 1252950072
Principal investigator 1 ModernaTX, Inc. $1,910.00 05/02/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?50 Years of Age No dispute reported 06/30/2026 1252950036
Principal investigator 1 ModernaTX, Inc. $14,723.10 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994354
Principal investigator 1 ModernaTX, Inc. $35,739.00 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994366
Principal investigator 1 ModernaTX, Inc. $16,701.00 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994418
Principal investigator 1 ModernaTX, Inc. $7,168.70 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994422
Principal investigator 1 ModernaTX, Inc. $2,004.00 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010372
Principal investigator 1 ModernaTX, Inc. $36.50 04/23/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH-NORFOLK
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994356
Principal investigator 1 SANOFI PASTEUR INC. $69,390.30 04/22/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226090747
Principal investigator 1 Janssen Research & Development, LLC $6,090.00 04/17/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175241050
Principal investigator 1 ModernaTX, Inc. $7,361.55 04/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994312
Principal investigator 1 ModernaTX, Inc. $20,276.58 04/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994396
Principal investigator 1 ModernaTX, Inc. $400.00 04/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994282
Principal investigator 1 ModernaTX, Inc. $435.00 04/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH-NORFOLK
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950056
Principal investigator 1 ModernaTX, Inc. $49.89 04/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH-NORFOLK
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994264
Principal investigator 1 ModernaTX, Inc. $8.50 03/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH-NORFOLK
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants No dispute reported 06/30/2026 1252950080
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $77,170.81 03/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH NORFOLK
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214125030
Principal investigator 1 Janssen Research & Development, LLC $1,857.60 03/24/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175240380
Principal investigator 1 ModernaTX, Inc. $24,494.80 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994328
Principal investigator 1 ModernaTX, Inc. $992.75 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994334
Principal investigator 1 ModernaTX, Inc. $6,604.40 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994374
Principal investigator 1 ModernaTX, Inc. $3,040.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010354
Principal investigator 1 ModernaTX, Inc. $1,336.00 03/24/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010362
Principal investigator 1 ModernaTX, Inc. $2,000.00 03/21/2025 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252950012
Principal investigator 1 ModernaTX, Inc. $1,600.43 03/19/2025 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252950058
Principal investigator 1 ModernaTX, Inc. $17,800.00 03/19/2025 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252950062
Principal investigator 1 SANOFI PASTEUR INC. $500.00 03/19/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226091373
Principal investigator 1 SANOFI PASTEUR INC. $136,429.30 03/19/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226091644
Principal investigator 1 SANOFI PASTEUR INC. $800.00 03/19/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226114843
Principal investigator 1 ModernaTX, Inc. $2,800.00 03/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994306
Principal investigator 1 ModernaTX, Inc. $1,000.00 03/13/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994388
Principal investigator 1 ModernaTX, Inc. $145.60 03/10/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH-NORFOLK
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252950022
Principal investigator 1 SANOFI PASTEUR INC. $130,965.10 03/03/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226090983
Principal investigator 1 ModernaTX, Inc. $104.00 02/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH-SPRINGDALE
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252949984
Principal investigator 1 ModernaTX, Inc. $8,046.50 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994332
Principal investigator 1 ModernaTX, Inc. $750.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994352
Principal investigator 1 ModernaTX, Inc. $686.85 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994360
Principal investigator 1 ModernaTX, Inc. $2,866.15 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994368
Principal investigator 1 ModernaTX, Inc. $250.80 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994372
Principal investigator 1 ModernaTX, Inc. $23,659.75 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994378
Principal investigator 1 ModernaTX, Inc. $11,913.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994424
Principal investigator 1 ModernaTX, Inc. $3,006.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010382
Principal investigator 1 Janssen Research & Development, LLC $5,416.00 02/19/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175240271
Principal investigator 1 ModernaTX, Inc. $83.20 02/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH-SPRINGDALE
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252950064
Principal investigator 1 ModernaTX, Inc. $5,732.30 02/19/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994338
Principal investigator 1 SANOFI PASTEUR INC. $500.00 02/13/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226092343
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 02/06/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226115356
Principal investigator 1 ModernaTX, Inc. $2,400.00 02/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994272
Principal investigator 1 SANOFI PASTEUR INC. $1,890.00 02/03/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226092358
Principal investigator 1 SANOFI PASTEUR INC. $5,550.00 02/03/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226092376
Principal investigator 1 SANOFI PASTEUR INC. $500.00 02/03/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226092395
Principal investigator 1 SANOFI PASTEUR INC. $26,863.20 02/03/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase I/II Study to Investigate the Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccines MRT5421, MRT5424, and MRT5429 in Healthy Participants Aged 18 Years and Above No dispute reported 06/30/2026 1226092414
Principal investigator 1 ModernaTX, Inc. $418.50 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994394
Principal investigator 1 ModernaTX, Inc. $14,812.80 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994400
Principal investigator 1 ModernaTX, Inc. $4,251.52 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994402
Principal investigator 1 ModernaTX, Inc. $57,231.69 01/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age No dispute reported 06/30/2026 1252994408
Principal investigator 1 SANOFI PASTEUR INC. $44,815.40 01/29/2025 Non-covered Recipient Entity
Velocity Clinical Research,inc
A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older No dispute reported 06/30/2026 1226092348
Principal investigator 1 ModernaTX, Inc. $13,639.15 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994284
Principal investigator 1 ModernaTX, Inc. $1,630.20 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994326
Principal investigator 1 ModernaTX, Inc. $11,464.60 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994330
Principal investigator 1 ModernaTX, Inc. $4,305.40 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994376
Principal investigator 1 ModernaTX, Inc. $12,905.75 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994382
Principal investigator 1 ModernaTX, Inc. $1,520.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010356
Principal investigator 1 ModernaTX, Inc. $12,540.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010374
Principal investigator 1 ModernaTX, Inc. $4,008.00 01/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010380
Principal investigator 1 Janssen Research & Development, LLC $1,674.00 01/21/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175239649
Principal investigator 1 Janssen Research & Development, LLC $676.00 01/17/2025 Non-covered Recipient Entity
Velocity Clnc Research, Inc.
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175240885
Principal investigator 1 Seqirus USA Inc $471.60 01/17/2025 Non-covered Recipient Entity
Velocity Clinical Research, Inc.
A Phase 2, Multi-Center, Randomized, Observer-Blind Study, to Evaluate Safety and Immunogenicity of Homologous or Heterologous Priming and Booster Vaccinations with H5N8 or H5N6 MF59-adjuvanted, Cell Culture-derived Influenza Vaccine in Healthy Subjects >18 Years of Age No dispute reported 06/30/2026 1185277375
Principal investigator 1 ModernaTX, Inc. $600.00 01/10/2025 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252950010
Principal investigator 1 ModernaTX, Inc. $1,200.00 01/10/2025 Non-covered Recipient Entity
MERIDIAN CLINICAL RESEARCH LLC
A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive No dispute reported 06/30/2026 1252950060
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $137,866.59 01/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH NORFOLK
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214125322